Table 1

Baseline characteristics

 Vitamin DPlacebo
n=13n=14
Age (years)56 (10)57 (9)
Female10 (77)9 (64)
Ethnicity
 European10 (77)9 (64)
 Indian1 (8)3 (21)
 Other1 (8)2 (14)
Weight (kg)75 (19)72 (13)
Dietary calcium intake (mg/day)730 (670)660 (330)
Smoking status
 Current3 (23)0 (0)
 Never smoked8 (63)9 (64)
Glucocorticoid use
 Past oral use7 (54)9 (64)
 Current oral use1 (8)0 (0)
 Current inhaled use6 (46)1 (7)
Sarcoidosis extent
 Pulmonary involvement11 (85)8 (57)
 Extrapulmonary involvement6 (46)7 (50)
Chest radiograph stage at baseline
 01 (10)6 (46)
 11 (10)1 (8)
 21 (10)0 (0)
 33 (30)4 (31)
 44 (40)2 (15)
Bone density (g/cm2)
 Lumbar spine1.16 (0.19)1.13 (0.11)
 T score−0.2 (1.6)−0.6 (0.9)
 Total hip0.95 (0.11)0.93 (0.11)
 T score−0.6 (0.9)−0.8 (0.9)
 Femoral neck0.89 (0.13)0.91 (0.09)
 T score−1.2 (1.0)−0.9 (0.7)
 Total body1.15 (0.10)1.11 (0.07)
Adjusted serum calcium (mmol/L)2.24 (0.06)2.26 (0.12)
Serum phosphate (mmol/L)1.23 (0.15)1.06 (0.17)
Serum creatinine (mmol/L)74 (14)77 (12)
24 h urine calcium (mmol/day)4.6 (3.4)6.6 (5.2)
Screening 25-hydroxyvitamin D (nmol/L)*35 (12)38 (9)
Baseline 25-hydroxyvitamin D (nmol/L)*40 (17)45 (17)
1,25-dihydroxyvitamin D (pmol/L)109 (34)116 (25)
Parathyroid hormone (pmol/L)4.0 (1.6)4.9 (2.0)
P1NP (ug/L)37 (12)40 (15)
β-CTX (ng/L)310 (130)360 (210)
  • *25-Hydroxyvitamin D were measured at the screening study visit using a Diasorin assay, while the baseline 25-hydroxyvitamin D at the first study visit (average 3 weeks later) were stored frozen until the end of the study and then measured with a liquid chromatography tandem mass spectrometry assay (see text). Data are mean (SD) or n (%).

  • P1NP, serum procollagen type-I N-terminal propeptide; β-CTX, serum β-C-terminal telopeptide of type I collagen.